Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2015

View Archived Issues

Clinical evidence of the utility of a new drug delivery system for the treatment of autism

New device shows potential for monitoring patients under OAT

Uncovering a drug-targetable proinflammatory pathway associated with acute respiratory syndrome

Dipraglurant demonstrates efficacy in multiple preclinical models

Azapeptide analogue exerts cardioprotective effects

Genmab enters into license agreement with Novo Nordisk for DuoBody technology

Neurocrine completes enrollment in phase III trial of NBI-98854

Bristol-Myers Squibb patents factor XIa and KLKB1 inhibitors

Allergan describes formyl peptide modulators

Roche to acquire GeneWEAVE BioSciences

Bayer Schering Pharma patent details antimitotic agents

Neuropore Therapies divulges ASYN aggregation inhibitors

AbbVie reports TrK-A inhibitors

Funding supports Biogazelle's work on long non-coding RNAs in cancer

Proteon initiates second phase III study of vonapanitase

FDA approves IND for Saniona's NS-2359 in the treatment of cocaine addiction

AXIM conducting clinical trials of MedChew RX chewing gum in Europe

Merck & Co. discloses novel series of BACE1 inhibitors for AD

First patients randomized in phase IIa trial of SER-150 in diabetic nephropathy

CDC exercises contract options for Emergent's VIGIV program

Phase II BIRCH study of atezolizumab meets primary endpoint

Phase I/II study of INV-103 in systemic lupus erythematosus complete

Onconova Therapeutics submits IND for new phase III study of intravenous rigosertib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.